Ensemble, Alexion sign rare-disease drug collaboration

07/22/2013 | Xconomy · Genetic Engineering & Biotechnology News

Ensemble Therapeutics and a unit of Alexion Pharmaceuticals agreed to collaborate in the discovery and development of drugs for ultrarare diseases using the former's drug-discovery technologies and the Ensemblin macrocycles collection. Alexion will get the rights to develop and market drugs arising from the partnership. Ensemble is eligible to receive an upfront fee, research funding and milestone payments.

View Full Article in:

Xconomy · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID